Capillary Malformation-Arteriovenous Malformation Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 13, 2026 · Data accessed through Patsnap Life Sciences MCP servers.

This Capillary Malformation-Arteriovenous Malformation Indication Strategy Report ranks the opportunity using disease burden, biological rationale, unmet need, competitive intensity and transaction signals. It is designed for biopharma portfolio, search-and-evaluation, licensing and translational teams. The analysis focuses exclusively on Capillary Malformation-Arteriovenous Malformation; adjacent diseases are mentioned only when needed to interpret evidence or trial design.

Executive assessment

Capillary Malformation-Arteriovenous Malformation receives an overall strategic score of 68/100. The opportunity combines an unmet-need score of 82/100, competition score of 59/100 and market-attractiveness score of 73/100. Scores are directional decision aids, not forecasts: they synthesize the MCP evidence returned on the access date and explicitly penalize crowded development landscapes.

Disease background and strategic definition

An autosomal dominant inherited vascular disorder associated with loss of function mutations in the RASA1 or EPHB4 gene, encoding Ras GTPase-activating protein 1 or ephrin type-B receptor 4, respectively. It is characterized by cutaneous capillary malformations, often in association with arteriovenous malformations and arteriovenous fistulas, which may lead to abnormal bleeding, migraine headaches, seizures, and heart failure.

For indication strategy, the disease label is only the starting point. A credible target product profile should specify the treatable population, diagnostic pathway, severity threshold, prior-therapy requirements, measurable clinical outcomes and treatment setting. In Capillary Malformation-Arteriovenous Malformation, value creation will depend on selecting a phenotype that is biologically coherent and commercially reachable, while avoiding a trial population so narrow that recruitment and launch become impractical.

The disease record is identified by Patsnap disease ID f8146bd4d40b4bccbec9254f091bcb6f and MeSH identifier C564254. These identifiers help keep searches reproducible when synonyms or spelling variants change.

Epidemiology and disease-burden evidence

Evidence signal 1: 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

• In a Spanish registry covering 5.8 million people, CVI incidence was 3.37 per 1000 PY (95% CI, 3.31–3.43), increasing with age: 0.61 per 1000 PY in those <30 years of age and up to 10.95 per 1000 PY in those ≥80 years of age. Females pre­ sented with ≈2.5-fold more CVI than males (4.77 and 1.95 per 1000 PY, respectively). Venous stasis ulcer incidence was 0.23 per 1000 PY (95% CI, 0.21–0.24).138 • A Brazilian study with ≈870 000 public health care surgeries between 2009 and 2018 observed a rate of 4.52 CVI procedures per 10 000 PY at a cost of US $230 million.139 The in-hospital mortality rate was 0.0056%. • An online-based survey of 16 015 individuals from different nations showed a 22% prevalence of CVI, from 14% in French respondents to 37% in Russian respondents, and fewer than half of those with CVI sought medical attention.140 Among 19 104 work­ ers in Germany in a population-based study, the prevalence of CVI was similar (22.3%).141 Pulmonary Hypertension ICD-10 I27.0, I27.2. 2023, United States: Underlying cause mortal­ ity—9482. Any-mention mortality—33 614. 2022, United States: Hospital discharges—12 025 (principal diagnosis), 1 170 810 (all-listed diagnoses). Incidence • A 2023 analysis of a US claims database with ≈61 000 000 patients found a PH diagnosis in 5.2% of ≈855 000 of those who had chronic unex­ plained dyspnea. Furthermore, 0.1% had a diagno­ sis of PAH.142 • In the United States, PH accounted for 0.8% of all ED visits from 2011 to 2015, with a high hospi­ talization rate (87% of all patients with PH in the ED).143

Review the underlying epidemiology source

Evidence signal 2: Heart Disease and Stroke Statistics—2025 Update 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

• In a Spanish registry covering 5.8 million people, CVI incidence was 3.37 per 1000 PY (95% CI, 3.31–3.43), increasing with age: 0.61 per 1000 PY in those <30 years of age and up to 10.95 per 1000 PY in those ≥80 years of age. Females pre- sented ≈2.5-fold more CVI incidence than males (4.77 and 1.95 per 1000 PY, respectively). Venous stasis ulcer incidence was 0.23 per 1000 PY (95% CI, 0.21–0.24).133 • A Brazilian study with ≈870 000 public health care surgeries between 2009 and 2018 observed a rate of 4.52 CVI procedures per 10 000 PY at a cost of US $230 million.134 The in-hospital mortality rate was 0.0056%. • An online-based survey of 16 015 individuals from different nations showed a 22% prevalence of CVI, from 14% in French respondents to 37% in Russian respondents, and fewer than half of those with CVI sought medical attention.135 Among 19 104 work- ers in Germany in a population-based study, the prevalence of CVI was similar (22.3%).136 Pulmonary Hypertension ICD-10 I27.0, I27.2. 2022, United States: Underlying cause mortality—9635. Any-mention mortality—33 796. 2021, United States: Hospital discharges—12 855 (principal diagnosis), 1 131 494 (all-listed diagnoses). Incidence • A 2023 analysis of a US claims database with ≈61 000 000 patients found a PH diagnosis in 5.2% of ≈855 000 of those who had chronic unex- plained dyspnea. Furthermore, 0.1% had a diagno- sis of PAH.137 • In the United States, PH accounted for 0.8% of all ED visits from 2011 to 2015 with a high hos- pitalization rate (87% of all patients with PH in the ED).138 • PH incidence is somewhat highe

Review the underlying epidemiology source

Evidence signal 3: Epidemiology and Genetics of Venous Thromboembolism and Chronic Venous Disease

CVD is thought to affect >25 million adults in the United States with 6 to 7 million having advanced venous dis- ease,40 which is characterized by formation of VLU and accounts for this condition’s significant morbidity with >40% of these patients suffering from frequent recur- rences.41 Although it is well known that CVD is common in the general population, the true disease burden is diffi- cult to estimate given its spectrum of phenotypes, which are often misclassified. These phenotypes are delineated in the CEAP classification system (Clinical [C], Etiologi- cal [E], Anatomic [A], and Pathophysiological [P])42 (Fig- ure 1B); however, this system is not widely implemented outside of vascular specialties and therefore phenotypic classification including the diagnosis codes that describe a patient’s CVD are often inaccurate. For example, it is common to see patients with extensive venous reflux and symptomatic CVD with swelling and skin changes (CEAP 4) or patients that develop venous hypertension because of PTS or increased central pressures due to morbid obesity causing swelling (CEAP 3), inaccurately codified

Review the underlying epidemiology source

Epidemiology must be translated into an addressable population rather than copied into a revenue model. The recommended funnel is total prevalent or incident population → diagnosed population → clinically eligible segment → treated population → realistically accessible population. Analysts should separate point prevalence from lifetime prevalence, distinguish incidence from diagnosis rates, and avoid combining incompatible geographies or age bands.

For Capillary Malformation-Arteriovenous Malformation, the highest-value next epidemiology work is to quantify diagnostic delay, severity distribution, current treatment penetration and the proportion managed in specialist centers. Those variables often move the commercial case more than a single headline prevalence statistic.

Unmet need and patient-value thesis

Unmet need in Capillary Malformation-Arteriovenous Malformation should be framed as a measurable gap: inadequate disease control, treatment-limiting toxicity, burdensome administration, irreversible progression, delayed diagnosis, weak durability or lack of options for a defined subgroup. A program is strategically attractive when its mechanism can plausibly change one of those outcomes and when the clinical endpoint is accepted by regulators, physicians and payers.

The strongest development thesis would connect mechanism to a pre-specified responder population, demonstrate a clinically interpretable benefit, and reduce a meaningful part of the care burden. A weak thesis would rely only on statistical significance, use an endpoint disconnected from daily function, or assume that rarity automatically supports premium pricing.

Target mechanism: hERG

Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). Channel properties are modulated by cAMP and subunit assembly (PubMed:10837251). Characterized by unusual gating kinetics by producing relatively small outward currents during membrane depolarization and large inward currents during subsequent repolarization which reflect a rapid inactivation during depolarization and quick recovery from inactivation but slow deactivation (closing) during repolarization (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). Forms a stable complex with KCNE1 or KCNE2, and that this heteromultimerization regulates inward rectifier potassium channel activity (PubMed:10219239, PubMed:9230439). Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation. Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation.

The proposed mechanism anchor for this landscape is KCNH2. Target selection does not imply that every Capillary Malformation-Arteriovenous Malformation patient is target-dependent. The translational package should establish expression or pathway activity in the intended tissue, human genetic or biomarker support, pharmacodynamic tractability, a therapeutic window and evidence that target modulation changes disease-relevant biology.

Critical de-risking experiments include orthogonal target engagement assays, dose–response work in disease-relevant models, biomarker qualification, assessment of compensatory pathways and explicit off-target safety testing. Human evidence should be weighted above model-only evidence, and negative clinical results in related mechanisms should be treated as learning assets rather than ignored.

Clinical development and competitive landscape

The MCP search returned 17 matched registered studies overall. The most recent records sampled for this report are:

• JPRN-jRCT2041250168 — A Phase I/II, multicenter study to evaluate the safety, tolerability, pharmacokinetics characteristics, and efficacy of CYH33 in patinets with PIK3CA related overgrowth spectrum (PROS) and PIK3CA related vascular malformations (PRVM) (A Phase I/II study of CYH33 in Patients with PROS and PRVM); status: 募集中; phase: Phase 1/2; sponsor(s): not stated; enrollment: 81.
• NCT07015073 — Comparative of Sequential Application of Pulsed Dye Laser and Potassium-titanyl-phosphate Laser Treatment for Capillary Malformations Versus Single Application; status: Recruiting; phase: Not Applicable; sponsor(s): Hospital Universitario Ramón y Cajal; enrollment: 30.
• NCT06803667 — Radiofrequency Ablation of Vascular Anomalies; status: Not yet recruiting; phase: Not Applicable; sponsor(s): Baylor College of Medicine; enrollment: 15.

Raw trial count is not the same as commercial competition. Each program should be normalized by phase, modality, mechanism, sponsor strength, recruitment status, geography and the exact patient segment. Observational or investigator-led studies may reveal endpoint conventions and recruitment networks without representing product competition; discontinued assets may still expose safety or efficacy risks.

A differentiated Capillary Malformation-Arteriovenous Malformation program should define its advantage against the standard of care and the likely future standard at launch, not merely today's comparator. Useful whitespace can come from earlier intervention, a biomarker-selected subgroup, superior durability, safer chronic use, simpler delivery or a combination strategy with a clear contribution from each component.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned for Capillary Malformation-Arteriovenous Malformation. This is decision-relevant negative evidence: the indication may be under-transacted, may trade through broader disease labels, or may require target- and asset-level deal searches. It should not be interpreted as proof of zero partnering activity.

Transaction evidence should be interpreted alongside asset quality. Headline values may include contingent milestones, broad platform rights, multiple indications or undisclosed options. A defensible comparable set therefore requires matching disease, target, modality, development phase, territory and deal structure. Where direct comparables are sparse, triangulation across target-level and therapeutic-area transactions is preferable to forcing an unrelated deal into the valuation.

Potential partners will expect a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical development plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Early outreach is most productive when the program has a clear upcoming catalyst and a credible explanation of why the asset can win specifically in Capillary Malformation-Arteriovenous Malformation.

Market attractiveness and access considerations

The market opportunity is shaped by more than patient count. Diagnosis infrastructure, concentration of prescribers, treatment duration, administration setting, payer controls, competing generics, monitoring requirements and geographic reimbursement all influence attainable value. For Capillary Malformation-Arteriovenous Malformation, a launch model should test conservative, base and upside scenarios rather than assume uniform diagnosis and treatment.

Pricing power will depend on magnitude and durability of benefit, evidence quality, alternatives and budget impact. Developers should begin payer research before pivotal design so that endpoints, comparators and follow-up duration support both regulatory approval and reimbursement. Evidence generation should include health-resource use, quality of life and treatment burden when those are central to the value proposition.

Risks, evidence gaps and decision gates

• Disease-definition risk: validate that the proposed population is consistently diagnosed and recruitable.
• Biology risk: demonstrate that KCNH2 is causal or therapeutically relevant in the intended subgroup.
• Translation risk: link target engagement to a biomarker and a clinically meaningful endpoint.
• Competition risk: refresh the landscape before each investment gate and include mechanisms likely to launch first.
• Commercial risk: test diagnosis, access, pricing and adoption assumptions with physicians and payers.
• Data risk: treat zero-result searches as prompts for synonym and roll-up analysis, not definitive absence.

The recommended decision gates are: confirm epidemiology and segmentation; validate target biology in human evidence; establish a differentiated target product profile; obtain early clinical proof of mechanism; and only then scale investment toward registrational development or partnering. Each gate should have pre-agreed stop criteria.

Strategic recommendation

Capillary Malformation-Arteriovenous Malformation merits continued evaluation with an evidence-led, milestone-based strategy. The current signal supports prioritizing a narrowly defined population where KCNH2 biology can be measured and where the clinical benefit would be meaningful relative to available care. The program should advance only if follow-up work confirms population size, mechanistic coherence, endpoint feasibility and a credible route to differentiation.

For business development, the near-term goal is not to maximize the number of outreach targets; it is to assemble a partner-ready thesis that explains the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scores in this report provide a common language for comparing the opportunity while preserving the underlying evidence and uncertainties.

Methodology and source note

This report was assembled on August 13, 2026 using Patsnap MCP tools in a reproducible sequence: disease profile retrieval, epidemiology semantic search, target profile retrieval, clinical-trial search and pharmaceutical-deal search. Results reflect the returned records and query scope on that date. Counts may change as databases update, and the analysis is not medical, regulatory or investment advice.

The ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Qualitative judgments are informed by disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Readers should rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio decision.

Conclusion

Capillary Malformation-Arteriovenous Malformation offers a tractable strategic question: can a biologically grounded program deliver a material patient benefit in a clearly identifiable population and do so with sufficient differentiation to earn adoption? The evidence assembled here gives teams a starting map, while the identified gaps define the next diligence plan. Use the linked MCP marketplace to refresh the evidence as programs, trials and transactions evolve.